Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 1.00 |
| ▸ | RAB9A | P51151 | 12/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | HPGD | P15428 | 7/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.64 |
| ▸ | PKM | P14618 | 5/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3170855 | 1.00 | NPC1 (1.00) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL8957840 | 0.88 | NPC1 (0.78) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL227743 | 0.86 | NPC1 (0.78) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL12070687 | 0.85 | NPC1 (0.73) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL28460859 | 0.85 | RAB9A (0.73) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL29056665 | 0.85 | NPC1 (0.73) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL31429609 | 0.85 | RAB9A (0.73) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL8957841 | 0.83 | RAB9A (0.71) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL4117255 | 0.83 | NPC1 (0.71) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL5056430 | 0.82 | NPC1 (0.69) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403128-B2 | Compositions and methods for blocking sodium channels | Univerity of Virginia Patent Foundation (US) | 2025-09-02 | — | — | US | disclosed |
| US-12195432-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2024137505-A2 | METHOD OF IMPROVING CELL FITNESS IN AN EX-VIVO CELL POPULATION | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2022057930-A1 | BENZIMIDAZOLE COMPOUND HAVING ENDOTHELIAL LIPASE INHIBITION EFFECT, AND APPLICATION | 盐城师范学院 | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403128-B2 | Compositions and methods for blocking sodium channels | SCN3A, SCN1B, SCN2B | NPC1 483/4885RAB9A 2068/4885ALDH1A1 2497/4885 |
| US-12195432-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | NPC1 989/4885RAB9A 2214/4885ALDH1A1 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.